title: Treatment of autistic spectrum disorder with insulin-like growth factors.
abstract: There are no treatments for the core symptoms of autistic spectrum disorder (ASD), but there is now more knowledge on emerging mechanisms and on mechanism-based therapies. In autism there are altered synapses: genes affected are commonly related to synaptic and immune function. Dysregulation of activity-dependent signaling networks may have a key role the etiology of autism. There is an over-activation of IGF-AKT-mTor in autism spectrum disorders. Morphological and electro-physiological defects of the cerebellum are linked to system-wide ASD-like behavior defects. The molecular basis for a cerebellar contribution has been demonstrated in a mouse model. These have led to a potential mechanism-based use of drug targets and mouse models. Neurotrophic factors are potential candidates for the treatment. Insulin-like growth factor-1 (IGF-1) is altered in autism. It reduces neuro-inflammation: by causing changes of cytokines such as IL-6 and microglial function. IGF-1 reduces the defects in the synapse. It alleviates NMDA-induced neurotoxicity via the IGF-AKT-mTor pathway in microglia. IGF-1 may rescue function in Rett syndrome and ASD caused by changes of the SCHANK3 gene. There are recently pilot studies of the treatment of Rett syndrome and of SCHANK3 gene deficiency syndromes. The FDA has granted Orphan drug designations for Fragile X syndrome, SCHANK3 gene deficiency syndrome and Rett syndrome.
authors: Children's Hospital, University of Eastern Finland and Kuopio University Hospital, P. O. Box 1627, FI-70211 Kuopio, Finland. Electronic address: raili.riikonen@kolumbus.fi.
authors: Raili
authors: R
authors: Riikonen
mesh_terms: D000067877:Autism Spectrum Disorder / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism* / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
chemical_list: D015850:Interleukin-6; D007334:Insulin-Like Growth Factor I
keywords: Autism-spectrum disorder; Insulin-like growth factor; Therapy